Lawrence S Young

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9057492/publications.pdf

Version: 2024-02-01

		8755	10955
243	22,853	77	142
papers	citations	h-index	g-index

250	250	250	17098
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Transforming the UK's diagnostics agenda after COVID-19. Lancet, The, 2022, 399, 1606.	6.3	1
2	Epsteinâ€“Barr Virus (Herpesviridae). , 2021, , 267-277.		0
3	Pathogens: Journal Section Readjustment. Pathogens, 2021, 10, 72.	1.2	0
4	Advances in pathogenesis and precision medicine for nasopharyngeal carcinoma. MedComm, 2021, 2, 175-206.	3.1	24
5	The Role of EBV-Encoded LMP1 in the NPC Tumor Microenvironment: From Function to Therapy. Frontiers in Oncology, 2021, 11, 640207.	1.3	44
6	Whole-genome profiling of nasopharyngeal carcinoma reveals viral-host co-operation in inflammatory NF-Î°B activation and immune escape. Nature Communications, 2021, 12, 4193.	5.8	56
7	The EBV-Encoded Oncoprotein, LMP1, Recruits and Transforms Fibroblasts via an ERK-MAPK-Dependent Mechanism. Pathogens, 2021, 10, 982.	1.2	7
8	Long COVID risk - a signal to address sex hormones and women's health. Lancet Regional Health - Europe, The, 2021, 11, 100242.	3.0	48
9	Strategies for conjugating iridium(III) anticancer complexes to targeting peptides via copper-free click chemistry. Inorganica Chimica Acta, 2020, 503, 119396.	1.2	13
10	The Epstein-Barr Virus-Encoded EBNA1 Protein Activates the Bone Morphogenic Protein (BMP) Signalling Pathway to Promote Carcinoma Cell Migration. Pathogens, 2020, 9, 594.	1.2	5
11	The Therapeutic Potential of Targeting BARF1 in EBV-Associated Malignancies. Cancers, 2020, 12, 1940.	1.7	16
12	Single-cell transcriptomic analysis defines the interplay between tumor cells, viral infection, and the microenvironment in nasopharyngeal carcinoma. Cell Research, 2020, 30, 950-965.	5.7	111
13	A novel Epsteinâ€Barr virus subtype associated with nasopharyngeal carcinoma found in South China. Cancer Communications, 2020, 40, 60-62.	3.7	10
14	CD40L membrane retention enhances the immunostimulatory effects of CD40 ligation. Scientific Reports, 2020, 10, 342.	1.6	13
15	Discovery of selective, antimetastatic and anti-cancer stem cell metallohelicesviapost-assembly modification. Chemical Science, 2019, 10, 8547-8557.	3.7	23
16	Photoactive platinum(<scp>iv</scp>) complex conjugated to a cancer-cell-targeting cyclic peptide. Dalton Transactions, 2019, 48, 8560-8564.	1.6	17
17	An etiological role for the Epstein-Barr virus in the pathogenesis of classical Hodgkin lymphoma. Blood, 2019, 134, 591-596.	0.6	69
18	EBVâ€encoded miRNAs target ATMâ€mediated response in nasopharyngeal carcinoma. Journal of Pathology, 2018, 244, 394-407.	2.1	44

#	Article	IF	Citations
19	Activation of sterol regulatory elementâ€binding protein 1 (SREBP1)â€mediated lipogenesis by the Epsteinâ€“Barr virusâ€encoded latent membrane protein 1 (LMP1) promotes cell proliferation and progression of nasopharyngeal carcinoma. Journal of Pathology, 2018, 246, 180-190.	2.1	51
20	The Dynamic Roles of TGF-Î² Signalling in EBV-Associated Cancers. Cancers, 2018, 10, 247.	1.7	23
21	The EBV-Encoded Oncoprotein, LMP1, Induces an Epithelial-to-Mesenchymal Transition (EMT) via Its CTAR1 Domain through Integrin-Mediated ERK-MAPK Signalling. Cancers, 2018, 10, 130.	1.7	34
22	The role of metabolic reprogramming in Î³â€herpesvirusâ€associated oncogenesis. International Journal of Cancer, 2017, 141, 1512-1521.	2.3	14
23	Evidence of disrupted high-risk human papillomavirus DNA in morphologically normal cervices of older women. Scientific Reports, 2016, 6, 20847.	1.6	19
24	Epsteinâ€“Barr virus: more than 50 years old and still providing surprises. Nature Reviews Cancer, 2016, 16, 789-802.	12.8	575
25	The Epstein-Barr virus encoded LMP1 oncoprotein modulates cell adhesion via regulation of activin A/TGFÎ² and Î²1 integrin signalling. Scientific Reports, 2016, 6, 19533.	1.6	32
26	Artifacts in the data of Hu et al.. Nature Genetics, 2016, 48, 2-3.	9.4	18
27	Activation of the <scp>FGFR1</scp> signalling pathway by the Epsteinâ€“Barr virusâ€encoded <scp>LMP1</scp> promotes aerobic glycolysis and transformation of human nasopharyngeal epithelial cells. Journal of Pathology, 2015, 237, 238-248.	2.1	94
28	Pathogens Best Paper Awards for 2015. Pathogens, 2015, 4, 387-389.	1.2	0
29	Genome Diversity of Epstein-Barr Virus from Multiple Tumor Types and Normal Infection. Journal of Virology, 2015, 89, 5222-5237.	1.5	204
30	Abstract LB-093: Activation of the FGFR1 signaling pathway by the epstein-barr virus-encoded LMP1 promotes aerobic glycolysis and transformation of human nasopharyngeal epithelial cells. , 2015, , .		0
31	Epstein-Barr virus and nasopharyngeal carcinoma. Chinese Journal of Cancer, 2014, 33, 581-90.	4.9	184
32	Fas-associated factor (Faf1) is a novel CD40 interactor that regulates CD40-induced NF-ÎºB activation via a negative feedback loop. Cell Death and Disease, 2014, 5, e1213-e1213.	2.7	12
33	Epstein-Barr virus at 50-future perspectives. Chinese Journal of Cancer, 2014, 33, 527-528.	4.9	33
34	Epstein-Barr Virus: Nasopharyngeal Carcinoma and Other Epithelial Tumors. , 2014, , 953-970.		0
35	Epstein-Barr virus induction of the Hedgehog signalling pathway imposes a stem cell phenotype on human epithelial cells. Journal of Pathology, 2013, 231, 367-377.	2.1	65
36	Inhibition of the <scp>LKB1â€“AMPK</scp> pathway by the Epsteinâ€“Barr virusâ€encoded <scp>LMP1</scp> promotes proliferation and transformation of human nasopharyngeal epithelial cells. Journal of Pathology, 2013, 230, 336-346.	2.1	59

#	Article	IF	Citations
37	Contributions of the Epstein-Barr Virus EBNA1 Protein to Gastric Carcinoma. Journal of Virology, 2012, 86, 60-68.	1.5	78
38	A Global View of the Oncogenic Landscape in Nasopharyngeal Carcinoma: An Integrated Analysis at the Genetic and Expression Levels. PLoS ONE, 2012, 7, e41055.	1.1	49
39	Pathogens: A New Open Access Journal Serving All Those Interested in Infectious Disease. Pathogens, 2012, 1, 1-2.	1.2	1
40	Oncogenic human papillomavirus imposes an instructive pattern of DNA methylation changes which parallel the natural history of cervical HPV infection in young women. Carcinogenesis, 2012, 33, 1286-1293.	1.3	79
41	The role of the EBV-encoded latent membrane proteins LMP1 and LMP2 in the pathogenesis of nasopharyngeal carcinoma (NPC). Seminars in Cancer Biology, 2012, 22, 144-153.	4.3	270
42	Phase I/II trial of a dendritic cell vaccine transfected with DNA encoding melan A and gp100 for patients with metastatic melanoma. Gene Therapy, 2011, 18, 584-593.	2.3	41
43	Smoking initiation is followed by the early acquisition of epigenetic change in cervical epithelium: a longitudinal study. British Journal of Cancer, 2011, 104, 1500-1504.	2.9	36
44	Uterine Lymphatic and Blood Micro-Vessels in Women with Endometriosis through the Menstrual Cycle. Journal of Endometriosis, 2010, 2, 197-204.	1.0	10
45	Is Human Papillomavirus Viral Load a Clinically Useful Predictive Marker? A Longitudinal Study. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 832-837.	1.1	44
46	CD40 Ligand-Induced Carcinoma Cell Death: A Balance between Activation of TNFR-Associated Factor (TRAF) 3-Dependent Death Signals and Suppression of TRAF6-Dependent Survival Signals. Journal of Immunology, 2010, 184, 1111-1120.	0.4	36
47	Epstein-Barr virus-encoded EBNA1 inhibits the canonical NF-Î¹B pathway in carcinoma cells by inhibiting IKK phosphorylation. Molecular Cancer, 2010, 9, 1.	7.9	217
48	Upregulation of Id1 by Epstein-Barr Virus-encoded LMP1 confers resistance to TGFÎ²-mediated growth inhibition. Molecular Cancer, 2010, 9, 155.	7.9	40
49	Epstein-Barr virus-encoded EBNA1 enhances RNA polymerase III-dependent EBER expression through induction of EBER-associated cellular transcription factors. Molecular Cancer, 2010, 9, 241.	7.9	21
50	CD40 ligand induced cytotoxicity in carcinoma cells is enhanced by inhibition of metalloproteinase cleavage and delivery via a conditionally-replicating adenovirus. Molecular Cancer, 2010, 9, 52.	7.9	12
51	The contribution of the Epstein-Barr virus to the pathogenesis of childhood lymphomas. Cancer Treatment Reviews, 2010, 36, 348-353.	3.4	37
52	Cigarette smoking is an independent risk factor for cervical intraepithelial neoplasia in young women: A longitudinal study. European Journal of Cancer, 2010, 46, 405-411.	1.3	83
53	Abstract 5356: Inactivation of Foxo3a and increased expression of Id1 by the Epstein-Barr Virus-encoded LMP1 facilitates resistance to TGF-Î²-mediated growth inhibition in nasopharyngeal epithelial cells. , 2010, , .		0
54	Disruption of the E2 Gene Is a Common and Early Event in the Natural History of Cervical Human Papillomavirus Infection: A Longitudinal Cohort Study. Cancer Research, 2009, 69, 3828-3832.	0.4	75

#	Article	IF	Citations
55	A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma. Hepatology, 2009, 49, 124-132.	3.6	236
56	Prognostic impact of tumourâ€infiltrating Th2 and regulatory T cells in classical Hodgkin lymphoma. Hematological Oncology, 2009, 27, 31-39.	0.8	153
57	The ATM tumour suppressor gene is downâ€regulated in EBVâ€associated nasopharyngeal carcinoma. Journal of Pathology, 2009, 217, 345-352.	2.1	83
58	The EBV-encoded latent membrane proteins, LMP2A and LMP2B, limit the actions of interferon by targeting interferon receptors for degradation. Oncogene, 2009, 28, 3903-3914.	2.6	94
59	Epsteinâ€“Barr virus and carcinogenesis: beyond Burkitt's lymphoma. Clinical Microbiology and Infection, 2009, 15, 982-988.	2.8	100
60	A Phase I/II Clinical Trial in Localized Prostate Cancer of an Adenovirus Expressing Nitroreductase with CB1984. Molecular Therapy, 2009, 17, 1292-1299.	3.7	100
61	Role of the Epsteinâ€“Barr virus-encoded latent membrane protein-1, LMP1, in the pathogenesis of nasopharyngeal carcinoma. Future Oncology, 2009, 5, 811-825.	1.1	91
62	The Epsteinâ€“Barr virus oncoprotein, latent membrane proteinâ€1, reprograms germinal centre B cells towards a Hodgkin's Reedâ€“Sternbergâ€like phenotype. Journal of Pathology, 2008, 216, 83-92.	2.1	102
63	DNA tumour viruses promote tumour cell invasion and metastasis by deregulating the normal processes of cell adhesion and motility. European Journal of Cell Biology, 2008, 87, 677-697.	1.6	17
64	Expression of the Epstein-Barr Virus-Encoded Epstein-Barr Virus Nuclear Antigen 1 in Hodgkin's Lymphoma Cells Mediates Up-Regulation of CCL20 and the Migration of Regulatory T Cells. American Journal of Pathology, 2008, 173, 195-204.	1.9	162
65	Epstein-Barr Virus-Encoded LMP1 Regulates Epithelial Cell Motility and Invasion via the ERK-MAPK Pathway. Journal of Virology, 2008, 82, 3654-3664.	1.5	97
66	Epsteinâ€“Barr virus-encoded LMP1 induces a hyperproliferative and inflammatory gene expression programme in cultured keratinocytes. Journal of General Virology, 2008, 89, 2806-2820.	1.3	33
67	Combining gene and immunotherapy for prostate cancer. Prostate Cancer and Prostatic Diseases, 2008, 11, 187-193.	2.0	11
68	Epsteinâ€“Barr virus-encoded EBNA1 modulates the AP-1 transcription factor pathway in nasopharyngeal carcinoma cells and enhances angiogenesis in vitro. Journal of General Virology, 2008, 89, 2833-2842.	1.3	105
69	Down-regulation of the TGF-beta target gene, PTPRK, by the Epstein-Barr virusâ€“encoded EBNA1 contributes to the growth and survival of Hodgkin lymphoma cells. Blood, 2008, 111, 292-301.	0.6	96
70	CD154 Tone Sets the Signaling Pathways and Transcriptome Generated in Model CD40-Pluricompetent L3055 Burkittâ€™s Lymphoma Cells. Journal of Immunology, 2007, 179, 2705-2712.	0.4	14
71	Bmi-1 is induced by the Epstein-Barr virus oncogene LMP1 and regulates the expression of viral target genes in Hodgkin lymphoma cells. Blood, 2007, 109, 2597-2603.	0.6	89
72	IQGAP1 and IGFBP2. Journal of Neuropathology and Experimental Neurology, 2007, 66, 405-417.	0.9	84

#	Article	IF	Citations
73	EBV gene expression and regulation. , 2007, , 461-489.		36
74	Epsteinâ€“Barr virus-encoded EBNA1 regulates cellular gene transcription and modulates the STAT1 and TGFÎ² signaling pathways. Oncogene, 2007, 26, 4135-4147.	2.6	114
75	The natural history of cervical HPV infection: unresolved issues. Nature Reviews Cancer, 2007, 7, 11-22.	12.8	791
76	C4b Binding Protein Binds to CD154 Preventing CD40 Mediated Cholangiocyte Apoptosis: A Novel Link between Complement and Epithelial Cell Survival. PLoS ONE, 2007, 2, e159.	1.1	19
77	The role of cellular flice inhibitory protein (c-FLIP) in the pathogenesis and treatment of cancer. Expert Opinion on Therapeutic Targets, 2006, 10, 27-35.	1.5	47
78	Epstein-Barr virus (EBV) and its associated human cancers - Genetics, epigenetics, pathobiology and novel therapeutics. Frontiers in Bioscience - Landmark, 2006, 11, 2672.	3.0	116
79	Viral gene therapy strategies: from basic science to clinical application. Journal of Pathology, 2006, 208, 299-318.	2.1	297
80	The polycomb group proteins, BMI-1 and EZH2, are tumour-associated antigens. British Journal of Cancer, 2006, 95, 1202-1211.	2.9	39
81	CD40 mediated human cholangiocyte apoptosis requires JAK2 dependent activation of STAT3 in addition to activation of JNK1/2 and ERK1/2. Cellular Signalling, 2006, 18, 456-468.	1.7	44
82	Cancer gene-therapy: clinical trials. Trends in Biotechnology, 2006, 24, 76-82.	4.9	45
83	Epstein-Barr Virus Induces Cellular Transcription Factors to Allow Active Expression of EBER Genes by RNA Polymerase III. Journal of Biological Chemistry, 2006, 281, 33871-33880.	1.6	59
84	Targeting cellular FLICE-like inhibitory protein as a novel approach to the treatment of Hodgkinâ€™s lymphoma. Expert Review of Anticancer Therapy, 2006, 6, 911-919.	1.1	3
85	Role of Sexual Behavior in the Acquisition of Asymptomatic Epstein-Barr Virus Infection. Pediatric Infectious Disease Journal, 2005, 24, 498-502.	1.1	25
86	Induction of autotaxin by the Epstein-Barr virus promotes the growth and survival of Hodgkin lymphoma cells. Blood, 2005, 106, 2138-2146.	0.6	101
87	Constitutive activation of the CD40 pathway promotes cell transformation and neoplastic growth. Oncogene, 2005, 24, 7913-7923.	2.6	53
88	NF-Îºb overrides the apoptotic program of TNF receptor 1 but not CD40 in carcinoma cells. Cellular Signalling, 2005, 17, 729-738.	1.7	10
89	Proximity of first intercourse to menarche and the risk of human papillomavirus infection: A longitudinal study. International Journal of Cancer, 2005, 114, 498-500.	2.3	48
90	Constitutive activation of phosphatidyl-inositide 3 kinase contributes to the survival of Hodgkin's lymphoma cells through a mechanism involving Akt kinase and mTOR. Journal of Pathology, 2005, 205, 498-506.	2.1	164

#	Article	IF	Citations
91	Modulation of the Cell Growth Regulator mTOR by Epstein-Barr Virus-Encoded LMP2A. Journal of Virology, 2005, 79, 5499-5506.	1.5	114
92	Pituitary Tumor Transforming Gene Binding Factor: A Novel Transforming Gene in Thyroid Tumorigenesis. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 4341-4349.	1.8	53
93	Inhibition of NF-Î¹B enhances the cytotoxicity of virus-directed enzyme prodrug therapy and oncolytic adenovirus cancer gene therapy. Gene Therapy, 2005, 12, 1187-1197.	2.3	12
94	TRAF6 Is Required for TRAF2-Dependent CD40 Signal Transduction in Nonhemopoietic Cells. Molecular and Cellular Biology, 2005, 25, 9806-9819.	1.1	63
95	Activation of CD40 in Cervical Carcinoma Cells Facilitates CTL Responses and Augments Chemotherapy-Induced Apoptosis. Journal of Immunology, 2005, 174, 41-50.	0.4	63
96	The Epstein-Barr Virus-Encoded LMP2A and LMP2B Proteins Promote Epithelial Cell Spreading and Motility. Journal of Virology, 2005, 79, 1789-1802.	1.5	65
97	CD8+ T Cell Responses to the Polycomb Protein EZH2 in Patients with Haemopoietic Malignancies.. Blood, 2005, 106, 3914-3914.	0.6	0
98	Epstein-Barr virus-encoded LMP2A regulates viral and cellular gene expression by modulation of the NF-ÂB transcription factor pathway. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 15730-15735.	3.3	98
99	PTTCâ€™s C-terminal PXXP motifs modulate critical cellular processes in vitro. Journal of Molecular Endocrinology, 2004, 33, 663-677.	1.1	35
100	Expression of the cellular FLICE-inhibitory protein (c-FLIP) protects Hodgkin's lymphoma cells from autonomous Fas-mediated death. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 6611-6616.	3.3	109
101	Virus-Directed Enzyme Prodrug Therapy: Intratumoral Administration of a Replication-Deficient Adenovirus Encoding Nitroreductase to Patients With Resectable Liver Cancer. Journal of Clinical Oncology, 2004, 22, 1546-1552.	0.8	116
102	NITROREDUCTASE: A PRODRUG-ACTIVATING ENZYME FOR CANCER GENE THERAPY. Clinical and Experimental Pharmacology and Physiology, 2004, 31, 811-816.	0.9	102
103	Epsteinâ€“Barr virus: 40 years on. Nature Reviews Cancer, 2004, 4, 757-768.	12.8	1,875
104	Enhanced efficacy of Escherichia coli nitroreductase/CB1954 prodrug activation gene therapy using an E1B-55K-deleted oncolytic adenovirus vector. Gene Therapy, 2004, 11, 1126-1136.	2.3	47
105	Frequent epigenetic inactivation of the RASSF1A tumor suppressor gene in Hodgkin's lymphoma. Oncogene, 2004, 23, 1326-1331.	2.6	63
106	Epsteinâ€“Barr virus latent membrane protein 1 (LMP1) upregulates Id1 expression in nasopharyngeal epithelial cells. Oncogene, 2004, 23, 4488-4494.	2.6	46
107	An interferon-Î³ ELISPOT and immunohistochemical investigation of cytotoxic T lymphocyte-mediated tumour immunity in patients with paraneoplastic cerebellar degeneration and anti-Yo antibodies. Journal of Neuroimmunology, 2004, 150, 98-106.	1.1	22
108	Expression of tumor necrosis factor receptor-associated factor 1 in nasopharyngeal carcinoma: Possible upregulation by Epstein-Barr virus latent membrane protein 1. International Journal of Cancer, 2004, 112, 265-272.	2.3	16

#	Article	IF	Citations
109	Inhibition of Phosphatidylinositol 3-Kinase- and ERK MAPK-regulated Protein Synthesis Reveals the Pro-apoptotic Properties of CD40 Ligation in Carcinoma Cells. Journal of Biological Chemistry, 2004, 279, 1010-1019.	1.6	60
110	The role of the CD40 pathway in the pathogenesis and treatment of cancer. Current Opinion in Pharmacology, 2004, 4, 360-367.	1.7	83
111	CD40 expression in prostate cancer: A potential diagnostic and therapeutic molecule. Oncology Reports, 2004, 12, 679-82.	1.2	16
112	Carbonic anhydrase IX, a marker of hypoxia: correlation with clinical outcome in transitional cell carcinoma of the bladder. Oncology Reports, 2004, 11, 1005-10.	1.2	29
113	Absence of epsteinâ€“barr virus DNA in the tumor cells of european hepatocellular carcinoma. Virology, 2003, 306, 236-243.	1.1	53
114	Epsteinâ€“Barr virus nuclear antigen 1 (EBNA1) induced cytotoxicity in epithelial cells is associated with EBNA1 degradation and processing. Virology, 2003, 313, 663-676.	1.1	17
115	Immune enhancement of nitroreductase-induced cytotoxicity: Studies using a bicistronic adenovirus vector. International Journal of Cancer, 2003, 104, 104-112.	2.3	23
116	Epsteinâ€“Barr virus and oncogenesis: from latent genes to tumours. Oncogene, 2003, 22, 5108-5121.	2.6	450
117	Epsteinâ€“Barr virus-encoded latent infection membrane protein 1 regulates the processing of p100 NF-ÎºB2 to p52 via an IKKÎ³/NEMO-independent signalling pathway. Oncogene, 2003, 22, 7557-7569.	2.6	104
118	Human papillomavirus type 18 and rapidly progressing cervical intraepithelial neoplasia. Lancet, The, 2003, 361, 40-43.	6.3	64
119	Lack of evidence for an association of Epsteinâ€“Barr virus infection with breast carcinoma â€“ authors' response. Breast Cancer Research, 2003, 5, 1.	2.2	5
120	Epstein-Barr Virus Latent Membrane Protein 1 (LMP1) Activates the Phosphatidylinositol 3-Kinase/Akt Pathway to Promote Cell Survival and Induce Actin Filament Remodeling. Journal of Biological Chemistry, 2003, 278, 3694-3704.	1.6	250
121	Differential Induction of Nuclear Factor-ÎºB and Activator Protein-1 Activity after CD40 Ligation Is Associated with Primary Human Hepatocyte Apoptosis or Intrahepatic Endothelial Cell Proliferation. Molecular Biology of the Cell, 2003, 14, 1334-1345.	0.9	40
122	Seasonal differences in the onset of the EBV-positive and -negative forms of paediatric Hodgkin's lymphoma. British Journal of Cancer, 2003, 89, 1200-1201.	2.9	10
123	Mechanism of cell death induced by the novel enzyme-prodrug combination, nitroreductase/CB1954, and identification of synergism with 5-fluorouracil. British Journal of Cancer, 2003, 89, 944-950.	2.9	29
124	Inhibition of Metalloproteinase Cleavage Enhances the Cytotoxicity of Fas Ligand. Journal of Immunology, 2003, 170, 677-685.	0.4	48
125	TRAF1 Is a Critical Regulator of JNK Signaling by the TRAF-Binding Domain of the Epstein-Barr Virus-Encoded Latent Infection Membrane Protein 1 but Not CD40. Journal of Virology, 2003, 77, 1316-1328.	1.5	58
126	The effect of Epsteinâ€“Barr virus status on outcome in age- andsex-defined subgroups of patients with advanced Hodgkinâ€™s disease. Annals of Oncology, 2003, 14, 282-290.	0.6	41

#	Article	IF	Citations
127	Reactivity with A monoclonal antibody to Epstein-Barr virus (EBV) nuclear antigen 1 defines a subset of aggressive breast cancers in the absence of the EBV genome. Cancer Research, 2003, 63, 2338-43.	0.4	49
128	Epstein-Barr virus-associated cancers: aetiology and treatment. Herpes: the Journal of the IHMF, 2003, 10, 78-82.	0.3	8
129	The Oncogenic Protein Kinase Tpl-2/Cot Contributes to Epstein-Barr Virus-Encoded Latent Infection Membrane Protein 1-Induced NF-Î²B Signaling Downstream of TRAF2. Journal of Virology, 2002, 76, 4567-4579.	1.5	64
130	Population depletion activates autonomous CD154-dependent survival in biopsylike Burkitt lymphoma cells. Blood, 2002, 99, 3411-3418.	0.6	30
131	Interleukin 6 expression by Hodgkin/Reed-Sternberg cells is associated with the presence of â€˜Bâ€™ symptoms and failure to achieve complete remission in patients with advanced Hodgkin's disease. British Journal of Haematology, 2002, 118, 195-201.	1.2	66
132	Low prevalence of Epsteinâ€“Barr virus in incident gastric adenocarcinomas from the United Kingdom. British Journal of Cancer, 2002, 86, 702-704.	2.9	27
133	High incidence of cervical human papillomavirus infection in women during their first sexual relationship. BJOG: an International Journal of Obstetrics and Gynaecology, 2002, 109, 96-98.	1.1	146
134	Frequent expression of the tumor necrosis factor receptorâ€“associated factor 1 in latent membrane protein 1â€“Positive posttransplant lymphoproliferative disease and HIV-associated lymphomas. Human Pathology, 2001, 32, 963-969.	1.1	13
135	Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet, The, 2001, 357, 1831-1836.	6.3	720
136	Gene Therapy for Colorectal Cancer. BioDrugs, 2001, 15, 357-367.	2.2	13
137	Epstein-Barr virus and oncogenesis: From tumors to transforming genes. Perspectives in Medical Virology, 2001, , 229-252.	0.1	1
138	Bcl-2 expression identifies patients with advanced bladder cancer treated by radiotherapy who benefit from neoadjuvant chemotherapy. BJU International, 2001, 85, 829-835.	1.3	67
139	Expression of cytokine and chemokine genes in Epstein-Barr virus-associated nasopharyngeal carcinoma: comparison with Hodgkin's disease. Journal of Pathology, 2001, 194, 145-151.	2.1	83
140	Expression of the tumour necrosis factor receptor-associated factors 1 and 2 in Hodgkin's disease. Journal of Pathology, 2001, 194, 158-164.	2.1	34
141	LMP1 structure and signal transduction. Seminars in Cancer Biology, 2001, 11, 435-444.	4.3	203
142	The Transmembrane Domains of the EBV-Encoded Latent Membrane Protein 1 (LMP1) Variant CAO Regulate Enhanced Signalling Activity. Virology, 2001, 282, 278-287.	1.1	45
143	The Epsteinâ€“Barr Virus Encoded Latent Membrane Protein 2A Augments Signaling from Latent Membrane Protein 1. Virology, 2001, 289, 192-207.	1.1	40
144	Gene therapy for hepatocellular carcinomaâ€”teaching old dogs new tricks. Hepatology, 2001, 34, 207-209.	3.6	9

#	Article	IF	Citations
145	High-Level, Î²-Catenin/TCF-Dependent Transgene Expression in Secondary Colorectal Cancer Tissue. Molecular Therapy, 2001, 4, 365-371.	3.7	27
146	South Asian ethnicity and material deprivation increase the risk of Epstein-Barr virus infection in childhood Hodgkin's disease. British Journal of Cancer, 2001, 85, 350-356.	2.9	48
147	Combined Adenovirus-Mediated Nitroreductase Gene Delivery and CB1954 Treatment: A Well-Tolerated Therapy for Established Solid Tumors. Molecular Therapy, 2001, 3, 233-240.	3.7	48
148	CD40 activationâ€induced, Fasâ€dependent apoptosis and NFâ€ÎºB/APâ€1 signaling in human intrahepatic biliary epithelial cells. FASEB Journal, 2001, 15, 2345-2354.	0.2	115
149	Epsteinâ€“Barr virus infection: basis of malignancy and potential for therapy. Expert Reviews in Molecular Medicine, 2001, 3, 1-20.	1.6	49
150	The promise and potential hazards of adenovirus gene therapy. Gut, 2001, 48, 733-736.	6.1	46
151	In Vitro Assays to Study Epithelial Cell Differentiation. , 2001, 174, 173-180.		3
152	In Vitro Assays to Study Epithelial Cell Growth. , 2001, 174, 165-172.		5
153	CD40 INDUCED Fas-L EXPRESSION MAY CONTRIBUTE TO THE LOSS OF BILE DUCTS BY APOPTOSIS IN CHRONIC ALLOGRAFT REJECTION.. Transplantation, 2000, 69, S118-S119.	0.5	0
154	Sensitisation of human carcinoma cells to the prodrug CB1954 by adenovirus vector-mediated expression ofE. coli nitroreductase. , 2000, 86, 848-854.		71
155	Apoptosis of malignant cells in Hodgkin's disease is related to expression of the cdk inhibitor p27KIP1. , 2000, 190, 604-612.		22
156	Efficient nonviral transfection of dendritic cells and their use for in vivo immunization. Nature Biotechnology, 2000, 18, 1273-1278.	9.4	92
157	Expression of Escherichia coli B nitroreductase in established human tumor xenografts in mice results in potent antitumoral and bystander effects upon systemic administration of the prodrug CB1954. Cancer Gene Therapy, 2000, 7, 721-731.	2.2	63
158	Variation in the frequency of Epsteinâ€“Barr virus-associated Hodgkin's disease with age. Leukemia, 2000, 14, 748-753.	3.3	27
159	Gene therapy strategies for colon cancer. Trends in Molecular Medicine, 2000, 6, 82-87.	2.6	34
160	Identification of Functional Differences between Prototype Epsteinâ€“Barr Virus-Encoded LMP1 and a Nasopharyngeal Carcinoma-Derived LMP1 in Human Epithelial Cells. Virology, 2000, 272, 204-217.	1.1	71
161	CD40 Induces Apoptosis in Carcinoma Cells through Activation of Cytotoxic Ligands of the Tumor Necrosis Factor Superfamily. Molecular and Cellular Biology, 2000, 20, 5503-5515.	1.1	159
162	Immunotherapy in hepatocellular carcinoma. Lancet, The, 2000, 356, 784-785.	6.3	7

#	Article	IF	Citations
163	Inhibition of Human Breast Carcinoma Growth by a Soluble Recombinant Human CD40 Ligand. Blood, 1999, 93, 2999-3007.	0.6	133
164	Effect of Epstein-Barr Virus Infection on Response to Chemotherapy and Survival in Hodgkinâ€™s Disease. Blood, 1999, 94, 442-447.	0.6	70
165	Nuclear factor ÎºB in liver disease. Gut, 1999, 45, 170-171.	6.1	6
166	Activation of the p38 Mitogen-activated Protein Kinase Pathway by Epstein-Barr Virus-encoded Latent Membrane Protein 1 Coregulates Interleukin-6 and Interleukin-8 Production. Journal of Biological Chemistry, 1999, 274, 16085-16096.	1.6	311
167	CD40 Activation Induces Apoptosis in Cultured Human Hepatocytes via Induction of Cell Surface Fas Ligand Expression and Amplifies Fas-mediated Hepatocyte Death during Allograft Rejection. Journal of Experimental Medicine, 1999, 189, 441-446.	4.2	186
168	Effect of material deprivation on Epsteinâ€“Barr virus infection in Hodgkinâ€™s disease in the West Midlands. British Journal of Cancer, 1999, 80, 604-608.	2.9	27
169	Histologic and Immunologic Associations of an HPV16 Variant in LoSIL Smears. Gynecologic Oncology, 1999, 72, 56-59.	0.6	20
170	CD40 expression in bladder cancer. , 1999, 188, 38-43.		54
171	Epstein-Barr-virus infection and persistence: a B-cell marriage in sickness and in health. Lancet, The, 1999, 354, 1141-1142.	6.3	11
172	A longitudinal study of changes in endometrial microvascular density in norplantÂ® implant users. Contraception, 1999, 59, 123-129.	0.8	49
173	Molecular Evolution of the Metaplasia-Dysplasia-Adenocarcinoma Sequence in the Esophagus. American Journal of Pathology, 1999, 154, 965-973.	1.9	380
174	Epstein-Barr virus and apoptosis: viral mimicry of cellular pathways. Biochemical Society Transactions, 1999, 27, 807-812.	1.6	20
175	EBV AND APOPTOSIS: VIRAL MIMICRY OF CELLULAR PATHWAYS. Biochemical Society Transactions, 1999, 27, A134-A134.	1.6	0
176	Epstein-Barr Virus-Encoded Latent Membrane Protein 1 Activates the JNK Pathway through Its Extreme C Terminus via a Mechanism Involving TRADD and TRAF2. Journal of Virology, 1999, 73, 1023-1035.	1.5	194
177	Effect of Epstein-Barr Virus Infection on Response to Chemotherapy and Survival in Hodgkinâ€™s Disease. Blood, 1999, 94, 442-447.	0.6	15
178	Adenoviral delivery of B7â€“1 (CD80) increases the immunogenicity of human ovarian and cervical carcinoma cells. Gene Therapy, 1998, 5, 965-974.	2.3	37
179	Virus directed enzyme prodrug therapy for ovarian and pancreatic cancer using retrovirally delivered E. coli nitroreductase and CB1954. Gene Therapy, 1998, 5, 1061-1069.	2.3	92
180	Activation of the cJun N-terminal kinase (JNK) pathway by the Epstein-Barr virus-encoded latent membrane protein 1 (LMP1). Oncogene, 1998, 16, 1731-1742.	2.6	271

#	Article	IF	Citations
181	Epsteinâ€“Barr virus latent membrane protein-1 (LMP1) signalling is distinct from CD40 and involves physical cooperation of its two C-terminus functional regions. Oncogene, 1998, 17, 2383-2392.	2.6	59
182	Anti-proliferative activity and mechanism of action of titanocene dichloride. British Journal of Cancer, 1998, 77, 2088-2097.	2.9	131
183	Epstein-Barr virus gene expression in post-transplant lymphoproliferative disorders. Seminars in Immunopathology, 1998, 20, 389-403.	4.0	18
184	CD40 and epithelial cells: across the great divide. Trends in Immunology, 1998, 19, 502-506.	7.5	127
185	Analysis of Major Histocompatibility Complex Class I, TAP Expression, and LMP2 Epitope Sequence in Epstein-Barr Virusâ€“Positive Hodgkin's Disease. Blood, 1998, 92, 2477-2483.	0.6	133
186	Prolonged Phenotypic, Functional, and Molecular Change in Group I Burkitt Lymphoma Cells on Short-Term Exposure to CD40 Ligand. Blood, 1998, 92, 2830-2843.	0.6	46
187	Epstein-Barr virus gene expression in post-transplant lymphoproliferative disorders. Seminars in Immunopathology, 1998, 20, 389-403.	4.0	1
188	Functional Differences between BHRF1, the Epstein-Barr Virus-Encoded Bcl-2 Homologue, and Bcl-2 in Human Epithelial Cells. Journal of Virology, 1998, 72, 9016-9024.	1.5	37
189	Analysis of Major Histocompatibility Complex Class I, TAP Expression, and LMP2 Epitope Sequence in Epstein-Barr Virusâ€“Positive Hodgkin's Disease. Blood, 1998, 92, 2477-2483.	0.6	8
190	Prolonged Phenotypic, Functional, and Molecular Change in Group I Burkitt Lymphoma Cells on Short-Term Exposure to CD40 Ligand. Blood, 1998, 92, 2830-2843.	0.6	5
191	44 Involvement of Ceramide and JNK in CD40-Mediated Growth Inhibition. Biochemical Society Transactions, 1997, 25, S588-S588.	1.6	1
192	Antibody responses to HPV16 virus-like particles in women with cervical intraepithelial neoplasia infected with a variant HPV16. Lancet, The, 1997, 349, 1069-1070.	6.3	18
193	Epsteinâ€‰â€“â€‰Barr virus-encoded LMP1 and CD40 mediate IL-6 production in epithelial cells via an NF-ÎºB pathway involving TNF receptor-associated factors. Oncogene, 1997, 14, 2899-2916.	2.6	252
194	Gene directed enzyme prodrug therapy for cancer. Advanced Drug Delivery Reviews, 1997, 26, 173-184.	6.6	32
195	EPSTEIN-BARR VIRUS (EBV) INFECTION IN INFECTIOUS MONONUCLEOSIS: VIRUS LATENCY, REPLICATION AND PHENOTYPE OF EBV-INFECTED CELLS. , 1997, 182, 151-159.		188
196	Epstein-Barr virus infection and malignant lymphomas in liver transplant recipients. , 1997, 73, 514-520.		40
197	Introduction: Epsteinâ€“Barr virus and non-B cell tumours. Seminars in Cancer Biology, 1996, 7, 163-164.	4.3	2
198	In VitroProduction of Stable Epsteinâ€“Barr Virus-Positive Epithelial Cell Clones Which Resemble the Virus:Cell Interaction Observed in Nasopharyngeal Carcinoma. Virology, 1996, 215, 40-50.	1.1	68

#	Article	IF	Citations
199	Immunotherapy II: Antigens, receptors and costimulation. Cancer and Metastasis Reviews, 1996, 15, 329-349.	2.7	8
200	Endocrinology: The effect of high-dose medium- and long- term progestogen exposure on endometrial vessels. Human Reproduction, 1995, 10, 797-800.	0.4	52
201	The association of an HPV16 oncogene variant with HLA-B7 has implications for vaccine design in cervical cancer. Nature Medicine, 1995, 1, 464-470.	15.2	184
202	Epstein-Barr Virus Infection of CR2-Transfected Epithelial Cells Reveals the Presence of MHC Class II on the Virion. Virology, 1995, 213, 147-157.	1.1	16
203	Epstein-Barr Virus and Lymphomas: An Overview. , 1995, , 33-51.		1
204	Letters to the editor. Journal of Pathology, 1994, 172, 293-296.	2.1	0
205	EPstein-barr virus in inflammatory diseases of the liver and liver allografts: Anin situ hybridization study. Hepatology, 1994, 20, 899-907.	3.6	42
206	Epstein-Barr virus persistence and virus-associated tumours. Lancet, The, 1994, 343, 333-335.	6.3	166
207	PCR for the detection of cervical HPV16 infection: The need for standardization. International Journal of Cancer, 1993, 54, 700-701.	2.3	4
208	Overexpression of p53 in Hodgkin's disease: Lack of correlation with Epstein-Barr virus infection. Journal of Pathology, 1993, 169, 207-212.	2.1	38
209	P53 overexpression and Epstein-Barr virus infection in undifferentiated and squamous cell nasopharyngeal carcinomas. Journal of Pathology, 1993, 170, 457-461.	2.1	88
210	Epstein-Barr virus and carcinomas: rare association of the virus with gastric adenocarcinomas. British Journal of Cancer, 1993, 68, 1014-1019.	2.9	105
211	Overexpression of Wild-Type p53 and c-Myc in Human Fetal Cells Transformed with Adenovirus Early Region 1. Virology, 1993, 193, 579-591.	1.1	19
212	Epstein-Barr virus and carcinomas. International Journal of Clinical and Laboratory Research, 1993, 23, 17-24.	1.0	23
213	Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells.. Journal of Experimental Medicine, 1993, 177, 339-349.	4.2	354
214	HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2. Journal of Virology, 1993, 67, 7428-7435.	1.5	180
215	Transcripts from the Epstein-Barr virus BamHI A fragment are detectable in all three forms of virus latency. Journal of Virology, 1993, 67, 3182-3190.	1.5	119
216	PCR for the Detection of Genital Human Papillomavirus Infection: a Mixed Blessing. Annals of Medicine, 1992, 24, 215-219.	1.5	2

#	Article	IF	Citations
217	Epstein-Barr Virus and Carcinomas Expression of the Viral Genome in an Undifferentiated Gastric Carcinoma. Diagnostic Molecular Pathology, 1992, 1, 103-108.	2.1	14
218	Epstein-Barr Virus and Carcinomas Expression of the Viral Genome in an Undifferentiated Gastric Carcinoma. Diagnostic Molecular Pathology, 1992, 1, 103-108.	2.1	53
219	Immunohistochemical demonstration of the Epstein-Barr virus-encoded latent membrane protein in paraffin sections of Hodgkin's disease. Journal of Pathology, 1992, 166, 1-5.	2.1	131
220	Epsteinâ€“Barr virus infection and replication in a human epithelial cell system. Nature, 1992, 356, 347-350.	13.7	226
221	Elevated expression of ICAM1 (CD54) and minimal expression of LFA3 (CD58) in epstein-barr-virus-positive nasopharyngeal carcinoma cells. International Journal of Cancer, 1992, 50, 863-867.	2.3	39
222	Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts. Journal of Virology, 1992, 66, 2689-2697.	1.5	465
223	Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease. Lancet, The, 1991, 337, 320-322.	6.3	707
224	Epstein-Barr virus and carcinomas: Undifferentiated carcinomas but not squamous cell carcinomas of the nasopharynx are regularly associated with the virus. Journal of Pathology, 1991, 165, 17-24.	2.1	164
225	Expression of Epstein-Barr virus replicative proteins in aids-related non-Hodgkin's lymphoma cells. Journal of Pathology, 1991, 165, 289-299.	2.1	111
226	Epstein-Barr virus (EBV)-associated lymphoproliferative disease in the SCID mouse model: implications for the pathogenesis of EBV-positive lymphomas in man.. Journal of Experimental Medicine, 1991, 173, 147-158.	4.2	313
227	Differentiation-associated expression of the Epstein-Barr virus BZLF1 transactivator protein in oral hairy leukoplakia. Journal of Virology, 1991, 65, 2868-2874.	1.5	239
228	Epsteinâ€“Barr virus latent membrane protein inhibits human epithelial cell differentiation. Nature, 1990, 344, 777-780.	13.7	392
229	Expression of Epsteinâ€“Barr Virus Transformationâ€“Associated Genes in Tissues of Patients with EBV Lymphoproliferative Disease. New England Journal of Medicine, 1989, 321, 1080-1085.	13.9	804
230	Identification of a human epithelial cell surface protein sharing an epitope with the C3d/epstein-barr virus receptor molecule of B lymphocytes. International Journal of Cancer, 1989, 43, 786-794.	2.3	142
231	Two families of sequences in the small RNA-encoding region of Epstein-Barr virus (EBV) correlate with EBV types A and B. Journal of Virology, 1989, 63, 983-986.	1.5	94
232	Distinction between Epstein-Barr virus type A (EBNA 2A) and type B (EBNA 2B) isolates extends to the EBNA 3 family of nuclear proteins. Journal of Virology, 1989, 63, 1031-1039.	1.5	172
233	Epstein-Barr virus gene expression in malignant lymphomas induced by experimental virus infection of cottontop tamarins. Journal of Virology, 1989, 63, 1967-1974.	1.5	60
234	Expression of thec-fgr related transcripts in epstein-barr virus-associated malignancies. International Journal of Cancer, 1988, 42, 29-35.	2.3	11

#	Article	IF	Citations
235	Epstein-Barr virus-specific cytotoxic T-cell recognition of transfectants expressing the virus-coded latent membrane protein LMP. Journal of Virology, 1988, 62, 3747-3755.	1.5	115
236	Different patterns of Epstein-Barr virus gene expression and of cytotoxic T-cell recognition in B-cell lines infected with transforming (B95.8) or nontransforming (P3HR1) virus strains. Journal of Virology, 1988, 62, 894-901.	1.5	100
237	Epstein-barr virus-specific t-cell recognition of B-cell transformants expressing different ebna 2 antigens. International Journal of Cancer, 1987, 39, 373-379.	2.3	9
238	Epstein-Barr virus-transformed human precursor B cell lines: altered growth phenotype of lines with germline or rearranged but nonexpressed heavy chain genes. European Journal of Immunology, 1987, 17, 1199-1207.	1.6	71
239	Influence of the Epstein-Barr virus nuclear antigen EBNA 2 on the growth phenotype of virus-transformed B cells. Journal of Virology, 1987, 61, 1310-1317.	1.5	380
240	Pituitary gonadotrophin-releasing hormone receptor up-regulation in vitro: dependence on calcium and microtubule function. Journal of Endocrinology, 1985, 107, 49-56.	1.2	13
241	Gonadotrophin releasing hormone receptor regulation in relationship to gonadotrophin secretion. The Journal of Steroid Biochemistry, 1985, 23, 691-702.	1.3	30
242	Increased gonadotrophin releasing hormone receptors on pituitary gonadotrophs: effect on subsequent LH secretion. Molecular and Cellular Endocrinology, 1985, 41, 69-78.	1.6	32
243	Homologous ligand induction of pituitary gonadotrophin-releasing hormone receptors in vivo is protein synthesis dependent. Molecular and Cellular Endocrinology, 1984, 37, 139-144.	1.6	10